$12.59−0.01 (−0.08%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
Pharming Group (PHAR) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue compounds ~5.7%/yr (FY21→FY25), net margin 1.0%. Worth your attention in FY25: Share count (+8.2%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲35.1%
247.9
FY21→FY25CAGR +5.7%/yr
Net income ($M)—
2.5
one-off year: see footnoteCAGR −36.9%/yr
Free cash flow ($M)—
—
no FY25 valueCAGR —
Diluted EPS—
0.00
FY21→FY25CAGR −35.4%/yr
What the receipts whisper · what a headline number hides
Share count
+8.2%
648.7mn → 701.7mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
1¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 89.4% → 133.4%. Net margin 1.0% is more than double the sector median.
The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
| Line item | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|
| Revenue & profitability | |||||||
Revenue | 247.9 | 183.5 | 124.6 | 205.6 | 198.9 | ▲35.1% | +5.7% |
Cost of revenue | 45.5 | 35.4 | 25.2 | 17.6 | 21.0 | ▲28.5% | +21.3% |
Gross profit | 330.6 | 261.8 | 220.1 | 188.1 | 177.7 | ▲26.3% | +16.8% |
Research & development | 100.4 | 83.1 | 68.9 | 52.5 | 70.4 | ▲20.7% | +9.3% |
Selling, general & admin | 80.0 | 70.7 | 55.9 | 46.0 | 37.0 | ▲13.2% | +21.3% |
Total operating expenses | 180.3 | 153.8 | 124.8 | 184.3 | 166.8 | ▲17.2% | +2.0% |
Operating incomefeeds ROC rank | 22.1 | −5.7 | −25.4 | 18.2 | 13.6 | — | +13.0% |
Other income, net | −9.3 | −2.8 | 13.3 | −3.2 | 9.5 | — | — |
Pretax income | 12.8 | −8.5 | −12.0 | 15.0 | 23.1 | — | −13.6% |
Income tax | 10.3 | 3.3 | −1.5 | 1.3 | 7.1 | ▲207.9% | +9.8% |
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings | 2.5 | −11.8 | −10.5 | 13.7 | 16.0 | — | −36.9% |
| Per share | |||||||
Diluted EPSbuyback-sensitive | 0.00 | −0.02 | −0.02 | 0.02 | 0.02 | — | −35.4% |
Diluted shares (mn) | 701.68 | 680.31 | 671.07 | 656.35 | 648.75 | ▲3.1% | +2.0% |
| Margins | |||||||
Gross margin100th pct in Healthcare | 133.4% | 142.7% | 176.6% | 91.5% | 89.4% | ▼9.3pp | +44.0pp |
Operating margin | 8.9% | −3.1% | −20.3% | 8.9% | 6.8% | ▲12.0pp | +2.1pp |
Net margin54th pct in Healthcare | 1.0% | −6.5% | −8.5% | 6.7% | 8.0% | ▲7.5pp | −7.0pp |
FY21 effective tax rate was 31% vs a 12% norm for this window, likely a one-time item; see the filing.FY24 effective tax rate was −39% vs a 12% norm for this window, likely a one-time item; see the filing.
3 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-04-13 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Pharming Group's revenue last fiscal year?
Pharming Group reported revenue of $247.9M in fiscal 2025, up 35.1% from fiscal 2024.
What was Pharming Group's net income?
Pharming Group reported net income of $2.5M in fiscal 2025, a net margin of 1.0%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

